(Check out Carter’s worthcharting.com for actionable recommendations and live nightly videos.) Mid-cap biotech Immunovant is judged to be setup especially well for a move higher, by our work. In the throes of a “bearish-to-bullish” reversal, the stock exhibits bullish price-volume correlation and impressive relative strength to the market and to other biotechnology stocks. We’re buyers here. Price Objective: $40+/- This pair of identical charts of Immunovant tell the story: Source: FactSet DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Trending
- New allergy clinic first to use direct-care model for specialty care in Iowa
- Financial Data Transparency Act of 2022: Final Rule
- What happens to Satoshi’s BTC when Bitcoin’s quantum problem is fixed?
- This hidden investing flaw is costing you money. Talking to political opponents fixes it.
- Crypto Flows to Suspected Human Trafficking Surge 85% YoY, Chainalysis finds
- US major indices close higher on the day and on the week
- Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
- Can Starmer’s late-night World Cup openings help Britain’s struggling pubs? | Hospitality industry
Saturday, June 13
